Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Kiniksa Pharmaceuticals International has received a consensus recommendation of "Buy" from six covering brokerages, with an average price target of $41.17.
• The company reported earnings of $0.23 EPS, surpassing analysts' expectations, with a net margin of 0.90% for the recent quarter.
• Significant share transactions occurred, including insider selling, with over 679,686 shares sold by company insiders valued at about $21.27 million in the last quarter.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $41.1667.

KNSA has been the subject of several research analyst reports. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd.

Insider Activity

In related news, CAO Michael R. Megna sold 17,000 shares of the stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer owned 33,041 shares in the company, valued at $1,068,876.35. This represents a 33.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John F. Paolini sold 29,325 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total transaction of $954,528.75. Following the sale, the insider owned 57,403 shares of the company's stock, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 655,532 shares of company stock worth $20,622,436 over the last 90 days. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of KNSA. Geode Capital Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock worth $9,744,000 after purchasing an additional 9,654 shares during the period. Wells Fargo & Company MN boosted its stake in Kiniksa Pharmaceuticals International by 54.7% during the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock worth $417,000 after purchasing an additional 7,463 shares during the period. Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 4th quarter worth $3,955,000. Barclays PLC boosted its stake in Kiniksa Pharmaceuticals International by 11.2% during the 4th quarter. Barclays PLC now owns 71,896 shares of the company's stock worth $1,423,000 after purchasing an additional 7,267 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after acquiring an additional 29,300 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded up $0.53 during trading hours on Thursday, reaching $33.57. The stock had a trading volume of 584,624 shares, compared to its average volume of 672,465. The firm's 50 day moving average is $29.98 and its 200-day moving average is $25.72. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $34.55. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of 839.46 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.